Free Trial

Cepheid stock has been delisted and is no longer actively trading. Cepheid is now a division of Danaher Corporation (NYSE:DHR).

NASDAQ:CPHD

Cepheid (CPHD) Stock Price, News & Analysis

Cepheid logo

About Cepheid Stock (NASDAQ:CPHD)

Advanced Chart

Key Stats

Today's Range
$52.95
$52.95
50-Day Range
N/A
52-Week Range
$25.09
$53.91
Volume
N/A
Average Volume
1.25 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company's systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The Company's systems integrate these steps and analyze biological samples in test cartridges. Its primary offering is the GeneXpert system, which integrates sample preparation in addition to Deoxyribonucleic acid (DNA) amplification and detection. The GeneXpert system is designed for a range of user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. It also offers the SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample.

Receive CPHD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cepheid and its competitors with MarketBeat's FREE daily newsletter.

CPHD Stock News Headlines

From Social Security to Social Prosperity?
In less than a decade, Social Security could be out of money. But a surprising plan from Trump’s inner circle may not just save the system — it could unlock a major opportunity for savvy investors. Financial insider Jim Rickards calls it “Social Prosperity,” and says those who act now could see the biggest gains.
Reducing the spread of hepatitis C
See More Headlines

CPHD Stock Analysis - Frequently Asked Questions

Cepheid (NASDAQ:CPHD) announced its quarterly earnings results on Thursday, July, 28th. The scientific and technical instruments company reported $0.05 earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.19. The business's quarterly revenue was up 10.2% compared to the same quarter last year.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cepheid investors own include Editas Medicine (EDIT), Nokia Oyj (NOK), Bristol-Myers Squibb (BMY), GE Aerospace (GE), Gilead Sciences (GILD), QUALCOMM (QCOM) and AK Steel (AKS).

Company Calendar

Last Earnings
7/28/2016
Today
4/27/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CPHD
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:CPHD) was last updated on 4/28/2025 by MarketBeat.com Staff
From Our Partners